Product Name: SYK (522-533) pY525+pY526+pT530
Product Number: PE-04AXF95
Size: | 200 µg | | Price: | 23.00 |
| 1 mg | | $US | 46.00 |
| 5 mg | | | 126.00 |
Peptide Name: SYK (522-533) pY525+pY526+pT530
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y525+Y526+T530 phosphorylation stimulate phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: DEN-pY-pY-KAQ-pT-HGK
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1908.7 Da
Peptide Purity Percent after Synthesis and Purification: <50
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: Not stable
Scientific Background: Syk is a protein-tyrosine kinase that is a member of the TK group of protein kinases in the Syk family. It is moderate to highly expressed in most tested human tissues, particularly in hematopoietic cells. It mediates cell proliferation, differentiation, and phagocytosis. In B cells, Syk plays a crucial role in intracellular signalling induced by oxidative stress as well as antigen receptor engagement. Syk is activated by phosphorylation at Y525 and Y526. Phosphorylation of Y348 and Y352 enhances the binding, phosphorylation and activation of PLC-gamma and the early phase of Ca(2+) mobilization via a PI 3-kinase-independent pathway. Phosphorylation of Y131 of Syk inhibits interaction with Bcr. Phosphorylation of Y323 of Syk inhibits B cell Ag receptor signalling and strongly dampens the Ca(2+) signal. Syk appears to be an oncoprotein (OP) and a tumour suppressor protein (TSP). Syk is an oncoprotein in retinoblastoma, which is upregulated and is required for tumour cell survival. Syk is a potential tumour suppressor in breast cancer, where it absence in primary breast tumours is correlated with poor outcomes. Syk deficient cells have increased motility that is restored to normalcy by replacement with wild-type Syk. It has been linked with the development of allergy, asthma, inflammation, gastric cancer, acute lymphoblastic leukemia, and acute myeloid leukemia.
